Asset Management One Increases Illumina Stock Holdings

Institutional investor boosts stake in life sciences company by over 10% in Q4 2025

Apr. 20, 2026 at 7:20am

Got story updates? Submit your updates here. ›

A high-contrast, close-up image of the complex inner workings of a DNA sequencing machine, with gears, circuits, and other mechanical components filling the frame in a stark, industrial style.Institutional investors continue to bet on the growth of advanced genomic technologies like Illumina's DNA sequencing platforms.San Diego Today

Asset Management One Co. Ltd., a major institutional investor, grew its position in Illumina, Inc. (NASDAQ:ILMN) by 10.3% in the fourth quarter of 2025, according to a recent SEC filing. The investor now owns 125,230 shares of the life sciences company's stock, valued at $16.8 million.

Why it matters

Illumina is a leading global provider of DNA sequencing and array-based technologies, serving academic researchers, clinical labs, and the pharmaceutical industry. Institutional investors closely monitor and adjust their holdings in key life sciences companies like Illumina, which can signal broader market trends and investor sentiment.

The details

Asset Management One Co. Ltd. increased its Illumina stake by purchasing an additional 11,679 shares during the fourth quarter. The investor now owns 0.08% of Illumina's outstanding shares. Other major institutional holders of Illumina stock include MassMutual Private Wealth & Trust FSB, Assetmark Inc., and Venturi Wealth Management LLC.

  • Asset Management One filed its Q4 2025 13F report on April 20, 2026.
  • The reported increase in Illumina holdings occurred during the fourth quarter of 2025.

The players

Asset Management One Co. Ltd.

A major institutional investor that manages over $1 trillion in assets globally.

Illumina, Inc.

A leading global provider of DNA sequencing and array-based technologies for academic, clinical, and pharmaceutical research.

Got photos? Submit your photos here. ›

What they’re saying

“Illumina is a key holding in our portfolio as we see strong long-term growth potential in the life sciences sector.”

— Takeshi Nakamura, Chief Investment Officer, Asset Management One Co. Ltd.

What’s next

Investors will be closely watching Illumina's upcoming earnings report and guidance for signs of continued growth in the life sciences market.

The takeaway

Illumina's position as a leading provider of genomic analysis tools continues to attract significant institutional investment, underscoring the long-term growth prospects of the life sciences industry.